Iterative design, synthesis, and experimental optimization improve synthetic macrocyclic peptide potency, selectivity, and permeability. The company collaborates with argenx on oral macrocycle programs.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Iterative design, synthesis, and experimental optimization improve synthetic macrocyclic peptide potency, selectivity, and permeability. The company collaborates with argenx on oral macrocycle programs.
2026-02-18: Unnatural Products and Novartis sign cardiovascular macrocyclic peptide agreement
2026-03-16: Unnatural Products raises $45 million Series B for macrocyclic peptide development
Program / service
Target / indication
Representative stage
Evidence & scope
Undisclosed candidate
Not disclosed · Not disclosed
未披露
Quantitative human results not confirmed in this review
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Unnatural Products closed a $45 million Series B led by The Venture Collective, with argenx, Droia, and existing investors participating. Funding supports its computational design, automated chemistry, high-throughput screening platform, and macrocyclic peptide pipeline. The oral-delivery strategy remains a development objective; this financing announcement does not establish human oral efficacy for a newly disclosed candidate.
Unnatural Products licensed an undisclosed cardiovascular program to Novartis. Terms include up to $100 million in upfront and pre-IND payments, plus up to $1.7 billion in later milestones and royalties. The platform supports oral and injectable macrocycles; the announcement does not establish the specific program’s route or imply all contingent payments have been received.
Ahead of the AHA meeting, an original report reviewed enlicitide analyses across PREVENT cardiovascular risk groups and an open-label extension. LDL cholesterol reductions were broadly consistent across risk categories and persisted through Week 104. The extension selected participants who had tolerated and adhered to treatment and lacked a control group, limiting generalization of its long-term findings.
Aurinia reported LUPKYNIS net product sales of $232.4 million for the nine months ended September 30, 2026, up 18%, including $79.4 million in the third quarter, up 12%. Total company revenue also includes licensing, collaboration, and royalty income. These are commercialization results for an approved oral cyclic peptide, rather than a new indication approval or clinical endpoint readout.
A new review connects peptide structure, formulation, screening, and pharmacokinetic testing in an evidence-based framework for oral drug discovery. It distinguishes architecture-led libraries, oral optimization of existing hits, and hybrid approaches. The scope includes cyclic and noncyclic peptides; the proposed framework organizes development evidence rather than demonstrating a new therapy or clinical benefit.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
